Share

July 2018; 5 (4) Clinical/Scientific NotesOpen Access

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
First published April 5, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000460
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1325

Share

Article Information

vol. 5 no. 4 e460
DOI: 
https://doi.org/10.1212/NXI.0000000000000460
PubMed: 
29629397
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 8, 2018
  • Accepted in final form March 5, 2018
  • First Published April 5, 2018.
Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Goran Rakocevic, MD, FAAN,
    2. Ubaldo Martinez-Outschoorn, MD and
    3. Marinos C. Dalakas, MD, FAAN
  1. Goran Rakocevic, MD, FAAN,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ubaldo Martinez-Outschoorn, MD and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. American Journal of Pathology, Editorial Board, 2012-2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Otsuka Pharmaceuticals

    Research Support, Government Entities:

    1. National Institutes of Health-National Cancer Institute of USA, Grant number: CA175193, (2013-2018)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Marinos C. Dalakas, MD, FAAN
    4. Scientific Advisory Boards:

    1. Serves on the CIDP steering committee for Novartis and on DSMB for Baxalta and Octapharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck/Serono, OCTAPHARMA, PFIZER AG

    Editorial Boards:

    1. 1. Neurology, editorial board (5 years, not compensated); 2)BMC Neurology (Section Editor, 5 years not compensated); 3) Acta Myologica, editorial board (5 years, not compensated); 5)Acta Neurologica Scandinavica editorial board ( 5 years, not compensated); 6)Therapeutic Advances in Neurology (Associate Editor; 4 years, compensated)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Therapath, Baxter, Octapharma, CSL, Dysimmune Diseases Foundation

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received Institutional support to Thomas Jefferson University Neurology department or to Neuroimmunology Unit, University of Athens Medical School for research and education from: Merck-Serono, Genzyme, Novartis, Guillain-Barre/CIDP Foundation, Dysimmune diseases Foundation, CSL, Biogen and Newfactor

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  1. Correspondence
    Dr. Dalakas marinos.dalakas{at}jefferson.edu
View Full Text

Article usage

Article usage: May 2018 to May 2023

AbstractFullPdfSource
Apr 2018026968Highwire
Apr 2018215362pmc
May 2018026132Highwire
Jun 2018014733Highwire
Jun 2018185778pmc
Jul 2018018330Highwire
Aug 2018119932Highwire
Aug 201874251pmc
Sep 201808912Highwire
Oct 2018010121Highwire
Nov 201807413Highwire
Dec 2018012311Highwire
Jan 201929218Highwire
Feb 201938914Highwire
Mar 201916810Highwire
Apr 20192458Highwire
May 20193458Highwire
Jun 201914717Highwire
Jul 201927226Highwire
Aug 2019214627Highwire
Sep 201913620Highwire
Oct 201925912Highwire
Nov 201916012Highwire
Dec 201903015Highwire
Jan 202014415Highwire
Feb 202003613Highwire
Mar 202013416Highwire
Apr 202012410Highwire
May 202002511Highwire
Jun 202003023Highwire
Jul 202002816Highwire
Aug 202003517Highwire
Sep 202003925Highwire
Oct 202013014Highwire
Nov 20201288Highwire
Dec 202002116Highwire
Jan 202132320Highwire
Feb 202101511Highwire
Mar 202113022Highwire
Apr 20211259Highwire
May 202103314Highwire
Jun 20211296Highwire
Jul 202102112Highwire
Aug 202113512Highwire
Sep 202103020Highwire
Oct 202113331Highwire
Nov 202102740Highwire
Dec 202102816Highwire
Jan 202201515Highwire
Feb 202211812Highwire
Mar 202202622Highwire
Apr 202201814Highwire
May 202212222Highwire
Jun 202202919Highwire
Jul 202204012Highwire
Aug 202205522Highwire
Sep 202214019Highwire
Oct 202223612Highwire
Nov 202216640Highwire
Dec 202214817Highwire
Jan 202306317Highwire
Feb 202305115Highwire
Mar 202306423Highwire
Apr 202303317Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles